---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108448"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:25:45.595516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Candel Q2 net loss $4.8M vs $22.2M loss a year ago; positive phase 3 CAN-2409 results in prostate cancer

## Summary
- Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.
- Phase 3 CAN-2409 in localized prostate cancer met primary endpoint with 30% improvement in DFS (HR 0.70, p=0.0155); RMAT designation received.
- BLA submission for CAN-2409 in prostate cancer expected in Q4 2026; cash $100.7M sufficient into Q1 2027.
- Appointed Charles Schoch as CFO and Maha Radhakrishnan to Board; completed $15M registered direct offering.
- Positive overall survival data from phase 2a CAN-2409 in NSCLC (mOS 24.5 months) and pancreatic cancer (mOS 31.4 months).

## SEC filing metadata
- accession: 0000950170-25-108448
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/0000950170-25-108448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108448
- JSON: https://secwatch.observer/filing/0000950170-25-108448.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.